1. Survival after HLA-Matched Sibling Donor HCT for ALL, Age ≥18 Years, 2005-2015
Older age at disease onset is a high-risk feature in ALL. Consequently, a larger proportion of ALL patients 18 years of age or older undergo allogeneic HCT for early disease. Among 4,335 patients ≥18 years of age receiving HLA-matched sibling HCT for ALL between , the 3-year survival probabilities were 59% ± 1%, 39% ± 2%, and 28% ± 2% for patients with early, intermediate, and advanced disease, respectively. The corresponding probabilities among the 5,557 recipients of unrelated donor HCT were 57% ± 1%, 38% ± 1%, and 25% ± 2% for early, intermediate, and advanced disease, respectively.